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Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disease affecting the neuromuscular system and does
not have a known singular cause. Genetic mutations,
extracellular factors, non-neuronal support cells, and
the immune system have all been shown to play
varied roles in clinical and pathological disease
progression. The therapeutic plasticity of mesenchymal
stem cells (MSCs) may be well matched to this
complex disease pathology, making MSCs strong
candidates for cellular therapy in ALS. In this review,
we summarize a variety of explored mechanisms by
which MSCs play a role in ALS progression, including
neuronal and non-neuronal cell replacement, trophic
factor delivery, and modulation of the immune system.
Currently relevant techniques for applying MSC therapy
in ALS are discussed, focusing in particular on delivery
route and cell source. We include examples from
in vitro, preclinical, and clinical investigations to
elucidate the remaining progress that must be made
to understand and apply MSCs as a treatment for ALS.ically; the remaining 10% are familial (fALS). Approximately
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Amyotrophic lateral sclerosis (ALS) is a rapidly progressing
neurodegenerative disease characterized by the loss of
upper and lower motor neurons (MNs). The mechanisms
of cell death and functional deficits, and consequently the
potential treatment approaches, are complex and varied.
Cell therapy approaches complement this complexity well
in their ability to respond to the host environment with
multiple mechanisms of repair. Recently, new potentials of
stem cells have been highlighted for the treatment of many
human diseases. While various types of stem cells are avail-
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2014have been broadly applied as treatment to many disease
types, including neurodegenerative diseases. In this review,
we discuss the investigation of stem cell therapy using
MSCs as a potential treatment for ALS. We describe the
strengths of MSCs for cell therapy, the potential mecha-
nisms of MSC actions in treating ALS, the design of MSC
treatment and delivery, and the recent translation of this
therapy from preclinical models into early-phase clinical
trials.Amyotrophic lateral sclerosis
Neurodegenerative diseases are characterized by the
progressive degeneration of selective neural populations
with subsequent functional loss. ALS, also known as Lou
Gehrig’s disease, is a fatal neurodegenerative disease caused
by the selective loss of MNs in the spinal cord and brain
stem. MN degeneration and neuromuscular junction
(NMJ) denervation rapidly result in decreased motor func-
tion. In humans, death typically results 3 to 5 years after
diagnosis because of respiratory failure after loss of
diaphragm control. About 90% of ALS cases occur sporad-
superoxide dismutase 1 (SOD1), TDP43, FUS, or
C90ORF72 genes [1]. Rat and mouse models overexpress-
ing mutated human SOD1 gene have been developed and
follow patterns of pathology and disease progression similar
to those observed in humans. These models are the basis
for most in vivo preclinical research probing the causes of
and potential treatments for ALS.
Although a disease cause of sporadic ALS has not been
specified, this disease is generally regarded as resulting
from factors involving environment, lifestyle, aging, and
genetic predisposition [2]. Several proposed pathological
mechanisms of disease include protein misfolding and
aggregation, glutamate excitotoxicity, oxidative stress,
mitochondrial dysfunction, glial cell activation and related
inflammatory processes, and axonal transport defects [3].
Currently, the only available treatment approved by US
Food and Drug Administration is riluzole, which has beenntral Ltd. The licensee has exclusive rights to distribute this article, in any
ion. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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months [4]. A treatment for ALS that more significantly
slows disease progression and improves quality of life
would drastically alter the prognosis for patients with this
disease.
Owing largely to the modest effects and partly to minor
concerns regarding side effects on the neuromuscular sys-
tem [5], development of new and effective therapies has
high priority and a variety of alternates are in various
stages of development and clinical trial. These therapies
include anti-glutamatergic, anti-oxidant, mitochondrial,
and anti-inflammatory agents [2]. Gene therapy has been
also explored for the delivery of supportive trophic factors.
Recently, stem cell therapy has been of great interest for
ALS treatment, particularly because of the potential for
multiple mechanisms of action.
Stem cell therapy
Cell therapy is a promising candidate for ALS treatment,
largely because of the selective MN death and the variety
of proposed mechanisms of degeneration that characterize
the disease. The primary aim of stem cell therapy in
neurodegenerative diseases is cell replacement, neuropro-
tection, or a combination of the two. Direct cell replace-
ment may be challenging because of the anatomical and
functional complexity of the central nervous system
(CNS), whereas neuroprotection may be a more feasible
short-term goal [6].
Multiple stem and progenitor cell types could have the
potential to either directly replace MNs and diseased glia
or provide support to slow degeneration. These cells
include pluripotent cells such as embryonic stem (ES)
cells and induced pluripotent stem (iPS) cells. ES and
iPS cells are attractive in their potential for replacement
of multiple cell types. Also, the establishment of a
method for inducing pluripotency from adult cells re-
duces ethical issues surrounding the use of ES cells [7].
However, doubts remain about the functional potency of
iPS cells, and these cells carry the risk of teratoma for-
mation [8]. Tissue-specific progenitors, which are cate-
gorized as adult stem cells, are also candidates for cell
therapy in neurodegenerative disease. These progenitor
cells include neural progenitor cells and MSCs. These
cells may be more accessible and more specific to the
therapeutic target. Cell type selection for stem cell ther-
apy must consider the likelihood of achievement of the
intended goals of cell replacement or neuroprotection,
along with availability, systemic effects on the host
organism, and cost. Most importantly, the selected cell
type must complement the intended therapeutic targets
in each disease application. The therapeutic plasticity of
MSCs matches the complex character of ALS well,
making MSCs strong candidates for treatment of this
disease.MSCs are firstly identified as stromal cells from the bone
marrow. These cells represent a small population of bone
marrow cells and also have been identified in different mes-
enchymal tissues of fetal or adult origin. Morphologically,
MSCs are mostly fusiform and fibroblast-like cells. The
cells can be identified by negative and positive profiling of
various hematopoietic surface markers, although differ-
ences exist among the reported studies in those surface
marker characteristics [9]. The essential characteristic of
MSCs is their ability to differentiate, either in vivo or
in vitro, into bone, stroma, cartilage, ligament/tendon,
and fat [10]. MSCs can be easily cultured to a large
scale in vitro under appropriate conditions. MSCs have
been known to express cytokines and growth factors such
as transforming growth factor-beta, interleukin-10 and −6,
insulin-like growth factor (IGF)-1, and vascular endothelial
growth factor (VEGF), which are potentially involved in
therapeutic contributions for neuronal protection and
reduced inflammation following transplantation [11,12].
MSCs have been applied as treatment to many disease
types, including neurodegenerative diseases. The safety of
their clinical use has been established for treatment of
hematopoietic disease. Treatment with human MSCs
(hMSCs) is being explored and has reached phase I and II
clinical trials in a variety of disease contexts, including
graft-versus-host disease, heart disease, and several neuro-
degenerative disorders [13-15]. In these contexts, MSCs
are recognized not only for their cell replacement capacity
but also for their ability to respond to the needs of the
host via secretion of supportive factors and modulation of
immune response. The immunoregulatory capacity, po-
tency, stability, and ease of harvest and expansion of
MSCs make them attractive candidates for cell therapy for
ALS. The delivery of these cells has been shown to slow
disease progression, delay disease onset, and/or increase
survival in preclinical models of ALS by a variety of
mechanisms. These preclinical studies will be discussed
further throughout this review.
Therapeutic applications of mesenchymal stem
cells for amyotrophic lateral sclerosis
Although more than a few studies have shown that MSC
transplantation results in disease measure improvement,
the exact mechanisms by which beneficial outcomes arise
are not entirely understood. The roles that MSCs can play
in the treatment of ALS are manifold . Several mecha-
nisms of repair and support, including cell replacement,
trophic factor or gene delivery, and immunomodulation
have been either attempted or observed, sometimes in
tandem [16]. These treatment mechanisms are illustrated
in Figure 1. Although the most effective combination of
mechanisms has not yet been established and optimized,
the therapeutic plasticity of MSCs for ALS treatment is an
asset of this approach [17].
Figure 1 Mechanisms of mesenchymal stem cell therapy in amyotrophic lateral sclerosis. (A) In the healthy patient, motor neuron viability
is maintained when supported by healthy astrocytes and oligodendrocytes. (B) In familial ALS, intrinsic and extrinsic factors contribute to the
degeneration of motor neurons. These factors are not well understood and remain under investigation. (C) Mesenchymal stem cells are well
suited to treat this complex disease because of their wide range of potential therapeutic responses, including direct cell replacement, trophic
factor delivery, and immunomodulation.
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Particularly for ALS, cell replacement therapy would be
expected to achieve one or both of two potential aims.
The first is to directly replace the degenerated MNs with
new, functional ones. The second is to provide support-
ive glial cells to protect and support MNs. Cell replace-
ment aims to provide a source of cells that will survive,
home to the region affected by disease, differentiate into
the intended cell type, and integrate into the surround-
ing neural circuitry [15]. If functional MN replacement
were achieved, it would presumably restore function and
ameliorate clinical symptoms. However, significant bar-
riers to this endpoint must be overcome in the process,
and astrocyte or oligodendrocyte replacement may be a
more achievable goal.
The MN replacement approach will not be successful
if there are extracellular factors contributing to the death
or dysfunction of cells. Several proposed mechanisms of
MN death in ALS, including glutamate excitotoxicity
and oxidative stress, might affect transplanted along with
endogenous neurons [18]. The temporal relationship be-
tween functional cell integration and disease progression
must also be considered [19]. In this anatomical context,
the process of homing, extending axons, and forming
functional synapses has not been shown to be achievable
within the time frame of ALS progression if cells are
transplanted at a symptomatic stage [20,21]. Even if this
can be achieved in humans, the question of whether
MSCs can form functional neurons in the spinal cord re-
mains unanswered.
Although the possibility of trans-differentiation of
grafted MSCs into neuronal phenotypes has been dem-
onstrated in some studies [22,23], their therapeutic con-
tribution is still uncertain. Such studies have provided
evidence of the ability of MSCs to differentiate into cells
with neuron-like morphology, gene expression, and pro-
tein expression. Recent work by Park and colleagues [24]
demonstrated a method for inducing differentiation ofMN-like cells from hMSCs in vitro. However, this
phenomenon is still controversial, particularly due to the
lack of evidence of functional synapse formation between
trans-differentiated MSCs. A recent in vivo study induced
in MSCs overexpression of neurogenin 1(Ngn1), a tran-
scriptional regulator that plays a role in initiating neuronal
differentiation. It was found that transplantation of MSCs-
Ngn1 improved MN survival in SOD1 mice but that
transplantation of unprocessed MSCs did not [25]. Al-
though no evidence that MSC-Ngn1 cells had differenti-
ated into neuronal cells was presented, this study did
show the increased ability of MSC-Ngn1 cells to migrate
to the spinal cord compared to unmodified MSCs. Given
the variety of challenges to replacement of MNs with
MSCs, other strategies are likely to be more efficacious.
The delivery of glial cells for neuroprotection may be a
more achievable goal. Although the loss of primary MNs
is the hallmark of ALS, increasing evidence is pointing
toward roles of dysfunctional glial cells in the disease
process. A recent study demonstrated that astrocytes
generated from tissue of patients with either familial or
sporadic ALS were selectively toxic to MNs [26], and an-
other found that astrocytes with the SOD1 mutation
prompted neurodegeneration in healthy wild-type (WT)
rodents [27]. Oligodendrocytes have also been shown to
display abnormal patterns of degeneration and cell
replacement in SOD1 mice [28]. In this study, the select-
ive removal of mutant human SOD1 expression from
oligodendrocytes in a mouse model delayed disease onset
and increased survival. This provides some explanation
for the results of several preclinical studies that found that
WT glial cells and glial-restricted precursors have positive
effects in treating ALS model rodents [29-31]. These
studies suggest that cell replacement with healthy, WT
astrocytes or oligodendrocytes derived from MSCs may
slow degeneration. This type of cell replacement, aimed at
neuroprotection, may be more functionally and patho-
logically feasible.
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The effectiveness of MSCs in improving ALS outcomes
may be due in part to their secretion of neurotrophic
factors, which play a variety of roles in normal neural
function and particularly in neural repair. Trophic/
growth factors are essential proteins for the mainten-
ance, function, differentiation, and proliferation of neural
cells. Supplementation with factors such as glial cell
line-derived neurotrophic factor (GDNF), VEGF, ciliary
neurotrophic factor, and IGF-1 is of interest as a possible
treatment of ALS. Virus-based delivery of these growth
factors has been shown to reduce MN vulnerability,
promote cell survival, and improve clinical outcomes in
SOD1 mice [32-34].
Similarly to viral vectors, MSCs can serve as effective
and stable delivery vehicles. They express or can be stably
transduced to overexpress trophic factors [23,35]. MSCs
also migrate toward injury sites, which may allow more
flexibility in treatment delivery when compared with viral
vectors [36,37]. Part of the recovery mechanism by trophic
factors may include endogenous restorative or regenerative
processes such as induction of endogenous neurogenesis,
gliogenesis, and synaptogenesis [38,39]. Neuroprotection,
as a result of the reduction of apoptosis, reduction of
demyelination, or an increase in astrocyte survival, is
another possible mechanism of action of MSCs expressing
neurotrophic factors [40,41].
Experimental studies have examined the effects of MSC-
based trophic factor delivery on ALS disease progression,
symptoms, and pathology. Recently, our group examined
the beneficial role of hMSCs genetically modified to stably
overexpress growth factors such as GDNF (hMSC-GDNF)
and VEGF (hMSC-VEGF). Intramuscular transplantation
of hMSC-GDNF significantly reduced NMJ denervation,
whereas unprocessed hMSCs did not. hMSC-GDNF also
protected large cholinergic MNs in the ventral horn and
increased survival of SOD1 rats [12]. We also showed that
hMSC-VEGF has positive effects on subject survival
comparable to those of hMSC-GDNF. Furthermore, the
combined delivery of GDNF and VEGF significantly slowed
disease progression, reduced endplate denervation, and en-
hanced MN survival when compared with either of the
growth factors delivered individually [42]. These studies
show that the expression of one or more growth factors
may improve the outcomes of MSC therapy by protecting
MNs and maintaining MN endplates.
Immunomodulation
Inflammation and immune response may play important
roles in the pathological progression of ALS [43]. Changes
in the morphology, number, and role of immune cells
both outside of and within the CNS are observed both
before symptom onset and throughout the disease [44].
Microglia, the immune cells of the CNS, may play bothprotective and toxic roles in ALS. The mechanisms of
activation and action of glial cells at different disease
stages are unclear. However, extensive evidence exists for
complex, non-cell autonomous cascades of degeneration
that ultimately contribute to MN damage [18].
MSCs may be well matched to these complicated pat-
terns of inflammation, as they have been shown to play a
variety of immunoregulatory roles (reviewed in [45]).
MSCs reduce the proliferation of B cells, T cells, and nat-
ural killer cells and slow the maturation of dendritic cells.
They also modulate immune cell function by reducing
antibody production by B cells, reducing or inhibiting acti-
vation of dendritic cells and T cells, and reducing cytokine
secretion by natural killer cells [46]. In the CNS, MSCs
have been shown to migrate to areas of inflammation and
reduce inflammation [47]. Several recent studies applying
MSCs in experimental models of ALS have indicated
attenuation of migroglial activation and reduction in
reactive astrogliosis as potential mechanisms of improved
clinical outcomes [21,48,49]. For these reasons, the immu-
nomodulatory roles that MSCs play may be an added
benefit of their use for cell therapy for ALS.Treatment strategy to design effective therapy
The technique and route of delivery of MSCs in ALS
must also be considered in developing the most effective
treatment approach [50]. Each potential mechanism dis-
cussed previously may be achievable in one or more ana-
tomical compartments, and selection of the most
efficient compartment is critical. Deliveries to the brain,
spinal cord, intrathecal space, venous system, and skel-
etal muscle have all been investigated in preclinical
models and may each be appropriate depending on the
study design and intended mechanism of repair. The
number of cell injections and time course of cell therapy
administration can also affect cell survival and clinical
outcomes. The major results from a selection of preclin-
ical studies treating rodent models of ALS with MSCs
are summarized in Table 1 for comparison of treatment
techniques and key results.Direct delivery into the central nervous system
Direct delivery of MSCs to the spinal cord, brain, or intra-
thecal space offers an efficient administration route to the
diseased areas and may reduce the volume of treatment
agent necessary. However, it may involve more clinical
complications because of the need for CNS surgery. The
proximity of the therapeutic agent to its target may
maximize the likelihood of cell replacement within the
time course of disease progression. Cell delivery to regions
of the spinal cord involved in limb and respiratory func-
tion is of particular interest, as loss of respiratory function
is the cause of death in most cases of human ALS.
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MSC therapy in ALS have focused on delivery to the
spinal cord [20,48,51-53]. Even though a small number
of MSCs were transplanted into the lumbar spinal cord,
they migrated well to the ventral horn and were located
in close proximity to MNs. An increase in MN number
and delay in motor function loss were observed [48].
Although spinal delivery has not resulted in significant
safety issues in clinical studies, concerns regarding
potential surgical damage to the diseased area and the
increasing evidence for non-replacement mechanisms of
MSC repair have prompted the investigation of other
delivery routes.
Intracerebroventricular and intrathecal deliveries avoid
direct intervention in the affected regions of the spinal
cord. Preclinical studies have shown similar effects when
compared with spinal transplantation, including in-
creased survival, delayed disease onset, and increased
MN survival in treated subjects [54,55]. Safety of these
delivery methods has also been indicated in clinical trials
[56-58].
Systemic or intramuscular delivery
The delivery of MSCs to tissues outside the CNS may
avoid complications related to surgery and could take
advantage of the plasticity of MSCs as therapeutic
agents. However, it may be less efficient than CNS deliv-
ery. It is expected that indirect delivery will require
greater doses for results comparable to those of direct
delivery, but this has not been established conclusively.
There is growing evidence for systemic and non-cell au-
tonomous mechanisms of neurodegeneration in ALS;
this evidence suggests that treatments delivered outside
the CNS may be appropriate [46,59].
Intravenous delivery of MSCs has been shown to
significantly improve disease measures in rodent ALS
models. In preclinical studies, MSCs administered intra-
venously into SOD1 mice resulted in cell migration to
various peripheral tissues as well as to the brain and
spinal cord [25,60-62]. Significant increase in life span
and delay of disease progression were observed in two of
these studies [60,61], and Uccelli and colleagues [61]
suggest reduced microglia activation and reduced oxida-
tive stress as potential mechanisms of repair. A recent
clinical study found no significant safety issues with this
delivery method and reported statistically significant
decreases in lymphocyte number, dendritic cells, and
lymphocyte proliferation after intravenous administra-
tion [56].
Cell delivery to the muscle has also been proposed
with the aims of maintaining and protecting the NMJ. In
preclinical studies, MSC therapy via intramuscular injec-
tion has been shown to reduce NMJ denervation,
improve MN survival, increase survival, and be aneffective trophic factor delivery technique in SOD1 ro-
dents [12,42]. Intramuscular delivery has the advantage
of proximity to the affected area without requiring direct
intervention into the CNS.
Delivery dose and time course
A challenge in comparing cell therapy techniques and
optimizing delivery strategy is the variety of approaches
that researchers employ with respect to number of injec-
tion sites, number of transplantation time points, and
cell dose, as shown in Table 1. Some researchers adopt a
multiple-transplant approach to improve cell survival,
whereas others deliver cells to multiple locations or with
multiple delivery routes [12,20,63]. These strategies may
allow an increased total cell dose while avoiding safety
complications that could result from one large adminis-
tration to a single location. Although phase I clinical tri-
als will help to determine safe cell doses, preclinical
studies directly comparing success of different treatment
approaches would aid in the selection of approaches for
clinical testing.
Cell source: autologous versus allogeneic
One of the advantages of MSCs in comparison with
other stem cell types is the relative ease of harvest and
ex vivo expansion, resulting in the possibility of autolo-
gous stem cell transplantation. This approach may
increase the safety of the technique in avoiding issues of
immune rejection while avoiding political and ethical
issues regarding stem cells derived from fetal sources
[15]. However, the patient-derived cells may have
reduced or altered therapeutic effects. Several recent
in vitro and in vivo studies suggest that MSCs and other
stem cells derived from patients with ALS may have
reduced pluripotency, hampered trophic factor secretion
efficiency, and toxic effects on MNs, particularly if
harvested at a later disease state [26,27,64,65].
These studies encourage further investigation into the
relative effects of autologous and allogeneic MSCs for
treating ALS. Most studies in experimental models have
used allogeneic MSCs with encouraging results. The use
of these cells is more affordable and, owing to the im-
munosuppressive roles that MSCs play, may not require
immunosuppression (and have even been used as a
treatment to graft-versus-host disease) [16].
Current clinical trials using mesenchymal stem
cells for amyotrophic lateral sclerosis
There have been several early-phase clinical trials of the
treatment of ALS with hMSCs [51,56,57,66]. Bone
marrow cells (BMCs), which may consist of mesenchy-
mal and hematopoietic stem cell types, have also been
investigated for cell therapy in ALS [52,53,67]. The
primary goal of these studies was to establish the safety
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these studies, autologous MSCs or BMCs were isolated
from patients, characterized, and used as treatment.
Four of these studies have delivered cells intraspinally
and found no significant safety issues related to the im-
plantation procedure [51-53,66]. In one of these studies,
histology performed on three patients revealed that the
MN number near the level of the graft (4.2 ± 0.8 MNs
per section at T4-T5) was significantly higher than that
farther from the graft (0.9 ± 0.3 MNs per section at T1,
T8-T9) and did not vary significantly between patients
[53]. No significant changes in disease progression were
recorded, although researchers reported anecdotal evi-
dence of improvement of symptoms. In two studies, cells
were delivered intrathecally or intravenously [56,57].
These report similar results with respect to safety and
response. One study that performed immunological
evaluation 24 hours after cell engraftment reported sig-
nificant reduction in activated lymphocytes and cytokine
production, indicating immediate immunomodulatory
effects of the hMSCs [56]. One study delivered stem
cells to the motor cortex; this delivery method involved
more safety complications [67].
Several proposed and ongoing clinical trials focus on
intrathecal delivery (National Institutes of Health Clinical-
Trials.gov identifiers NCT01082653 and NCT01142856),
and one explores intramuscular delivery and the delivery
of unspecified neurotrophic factors (NCT01051882). Once
the safety of all delivery methods is established, informa-
tion from human studies determining optimal cell dose
and from experimental studies determining the most effi-
cient and effective treatment method can be combined to
optimize the clinical application of hMSCs in ALS.
Conclusions
In the past decade, great accomplishments have been
made in the development and clinical translation of stem
cell therapies for ALS. MSCs stand out as cells capable
of protecting MNs, differentiating into multiple neural
cell types, modulating immune cell roles, and reducing
CNS inflammation. The success of MSCs in delaying
disease onset, improving motor function, and increasing
survival in preclinical models of ALS has resulted in
multiple clinical trials of MSC therapy in patients with
ALS. These trials have established the safety of MSC de-
livery for CNS applications, opening the door for larger
late-phase trials to better understand the effectiveness of
MSC therapy in humans. With this in mind, further
work is necessary to maximize the potential of MSC
therapy for ALS.
The establishment of the most effective technique for
delivering MSCs to patients is essential. As treatment
techniques in preclinical studies vary greatly between
groups of investigators, within-group studies comparingmultiple techniques may help elucidate the optimal
approach. In particular, studies comparing delivery
techniques alone or in combination, and investigating
resulting mechanisms of repair will clarify the most
important roles that MSCs play in treating ALS. In vivo
cell-tracking techniques are essential to aid these studies
and elucidate the initial distribution, migration, and
survival of engrafted cells.
Further studies examining the effectiveness of MSCs
overexpressing various growth factors to reduce MN
degeneration and improve clinical outcomes will help to
maximize the positive effects of cell therapy. In particu-
lar, overexpression of anti-inflammatory factors or those
that prevent misfolding and aggregation of proteins may
also be worthy of investigation. In this way, researchers
can, and should, take advantage of the therapeutic plasti-
city of MSCs. All potential reparative roles of MSCs
post-delivery, many of which are described above, should
be carefully considered and incorporated to maximize
the effectiveness of MSC therapy in ALS.
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